Journal of Medicinal Chemistry p. 8369 - 8384 (2017)
Update date:2022-08-15
Topics:
McDaniel, Keith F.
Wang, Le
Soltwedel, Todd
Fidanze, Steven D.
Hasvold, Lisa A.
Liu, Dachun
Mantei, Robert A.
Pratt, John K.
Sheppard, George S.
Bui, Mai H.
Faivre, Emily J.
Huang, Xiaoli
Li, Leiming
Lin, Xiaoyu
Wang, Rongqi
Warder, Scott E.
Wilcox, Denise
Albert, Daniel H.
Magoc, Terrance J.
Rajaraman, Ganesh
Park, Chang H.
Hutchins, Charles W.
Shen, Jianwei J.
Edalji, Rohinton P.
Sun, Chaohong C.
Martin, Ruth
Gao, Wenqing
Wong, Shekman
Fang, Guowei
Elmore, Steven W.
Shen, Yu
Kati, Warren M.
The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest. An effort to generate novel BET bromodomain inhibi
View MoreXi'an Galaxy Chemicals CO., Ltd
Contact:86-29-89380370
Address:No.8, Gaoxin three road, Xi'an city.
Shandong Bolode Bio-Technology Co., LTD
Contact:+86-0531-58966870
Address:136 Jingyi Road,Huaiyin District,Jinan,Shandong,China
Jiangxi Hessence Chemicals Co., Ltd.
Contact:+86 796 3511924
Address:Chengxi Industrial Park, Jishui County, Jiangxi Province 331600 China.
Contact:+8613400661290
Address:No 908,Kangwan Rd, Liuyang Economic
Contact:86-551-63540590
Address:No 1388 Furong Rd., Hefei, Anhui, China
Doi:10.1016/0022-328X(94)05275-G
(1995)Doi:10.7164/antibiotics.47.602
(1994)Doi:10.1007/s11178-005-0362-0
(2005)Doi:10.1021/jo00394a043
(1979)Doi:10.1021/ol0614774
(2006)Doi:10.1021/ja00901a061
(1963)
